# KLOW research-dose context — what the published studies used > Research-context summary of the doses and routes used in published preclinical work on KPV, GHK-Cu, BPC-157, and TB-500. No human dosing regimens. This page summarizes the experimental doses and administration routes reported in the preclinical literature for each KLOW component. It is research context, not a regimen, and no human dose for the blend has been established. ## The short version This page reports the experimental doses used in the published preclinical literature for each of the four KLOW components. These are doses the studies actually used, reported in third-person attribution to specific papers — they are not recommended human regimens, and none of the four components is FDA-approved for any human indication. A critical structural note applies across all four entries: the blend itself has no dose-response data. The 80 mg / 50:10:10:10 composition is a vendor convention describing how the vial is filled, not the result of a dose-finding study. Component half-lives also vary widely — BPC-157's formal pharmacokinetic study put the elimination half-life under about 30 minutes, while the tripeptides KPV and GHK-Cu clear faster still — which means a single co-formulated vial cannot maintain matched exposures across all four. Where a paper reports a specific dose, it is given as the dose used in that study; where the literature does not establish a dose, the absence is stated. ## What this page is and is not This page reports the experimental doses used in the published preclinical literature for each of the four KLOW components, with citation to the underlying paper. It is not a recommended regimen. None of the four components is FDA-approved for any human indication, no validated dose-response curve has been published for the four-peptide blend, and the doses below are research findings reported in third-person attribution to specific studies. Where a paper reports a dose, it is given as 'X dose was administered via Y route to Z species in [citation].' Where the literature does not establish a dose, the absence is stated explicitly. ## KPV — research-dose context In vitro, Dalmasso and colleagues used 10 nM in Caco2-BBE, HT29-Cl.19A, and Jurkat cells to demonstrate NF-κB and MAPK inhibition [1]. Land's mechanistic work in 16HBE14o- bronchial epithelial cells used 0.1-10 μg/mL [3]. The 2025 HaCaT keratinocyte study used 50 μg/mL against PM10 challenge [6]. For in-vivo work, Dalmasso administered KPV orally in drinking water at 100 μM to DSS- and TNBS-colitis mice [1]. Schaible and colleagues used a single 1 mg/kg intraperitoneal dose 30 minutes after controlled cortical impact in male C57Bl/6N mice [4]. Kannengiesser used systemic and oral routes in DSS and transfer colitis without a single canonical dose specified [2]. Recent translational work has shifted toward PepT1-targeted nanoparticle delivery rather than free KPV [5]. No human dose for KPV monotherapy has been established. KPV-related bulk drug substances are scheduled for FDA Pharmacy Compounding Advisory Committee evaluation on July 23, 2026. ## GHK-Cu — research-dose context The foundational transcriptomic dataset from Pickart and Margolina used 1-10 nM in cultured human dermal fibroblasts [7]. The Campbell COPD fibroblast restoration study used 10 nM [8]. The 2025 Mao colitis study used 20 mg/kg oral gavage daily for 14 days in male BALB/c mice [9]. Topical research has used composite hydrogel formulations (no single μg/cm² dose canonicalized across studies) in S. aureus-infected mouse wounds [10] and GHK-AgNP conjugates in similar paradigms [22]. The Leyden human cosmetic trial used a GHK-Cu cream twice daily for 12 weeks in 67 women with photodamaged skin — the active concentration is reported in the original protocol rather than as a per-application dose [11]. The topical cosmetic-dermatology literature on GHK-Cu spans decades. Systemic or injectable human dose-finding data is absent. ## BPC-157 — research-dose context The most-cited rodent dose for BPC-157 is 10 μg/kg intraperitoneally. Krivic used 10 μg/kg (along with 10 ng/kg and 10 pg/kg arms) IP daily in the Achilles tendon-to-bone healing study [12]. Cerovecki tested 10 μg/kg or 10 ng/kg IP, plus a 1.0 μg topical cream and 0.16 μg/mL in drinking water for oral administration, in 90-day MCL healing [13]. Novinscak used 10 μg/kg (and 10 ng/kg) IP and topical cream daily for 14 days in gastrocnemius crush injury [14]. BPC-157 was originally characterized as the 'stable gastric pentadecapeptide' on the basis of stability in human gastric juice, which underwrites the oral-route work in rodents. Plasma half-life is reported under 30 minutes in 2025 narrative reviews [21]. Human data is limited. The Vasireddi 2025 systematic review identified three human pilot studies — musculoskeletal/knee pain, interstitial cystitis, and intravenous safety — and explicitly recommended that off-label clinical use should not outpace the human evidence base [20]. No validated human dose has been established. ## TB-500 — research-dose context Reading the TB-500 dose literature requires the same flag carried through the rest of this monograph: most published dosing data attributed to 'thymosin beta-4' was generated with the full-length 43-amino-acid Tβ4 protein, not the seven-amino-acid TB-500 fragment. Malinda used 5 μg of Tβ4 in 50 μL PBS topically or intraperitoneally on 8 mm full-thickness punch wounds in Sprague-Dawley rats [16]. Sosne used 5 μg in 5 μL PBS twice daily as a topical ocular treatment in 129 Sv mice after alkali burn [17]. Bock-Marquette used intraperitoneal and intracardiac bolus dosing in coronary-ligation mice over a 4-week follow-up [18]. Smart and colleagues administered 150 μg intraperitoneally every 3 days to mobilize adult epicardial progenitors [19]. Native Tβ4 has a circulating half-life of approximately 2 hours in humans by ELISA. The TB-500 fragment is N-terminally acetylated to block aminopeptidase cleavage and improve in vitro stability, but published pharmacokinetics on the fragment in humans are sparse. No FDA-approved human dose exists. TB-500 is explicitly prohibited at all times by the World Anti-Doping Agency under category S2 (growth factors and growth-factor modulators). ## KLOW blend dose — what is and is not in the literature The most-cited research-vial composition is 80 mg total per vial: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg. A balanced 5 mg: 5 mg: 5 mg: 10 mg variant is also marketed. Component ratios vary across compounders. No controlled study has reported a dose-response curve for the four-peptide KLOW blend. The component-mass numbers above describe how vendors fill the vial; they do not describe a tested or recommended human dose. The combination has not been administered in any published controlled animal or human trial. --- An independent editorial monograph on the four-peptide KLOW research blend — not a clinic, not a pharmacy, not a vendor.